Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023

• Published in: Emerging Infectious Diseases Vol. 30; no. 6; pp. 1267 - 1270
• Main Authors: Kinoshita, Ryo, Miyamoto, Sho, Sakuraba, Shoko, Sugihara, Jun, Suzuki, Motoi, Suzuki, Tadaki, Yoneoka, Daisuke
• Format: Journal Article
• Language: English
• Published: United States Centers for Disease Control and Prevention (CDC) 01.06.2024; U.S. National Center for Infectious Diseases; Centers for Disease Control and Prevention
• Subjects: Adolescent; Adult; Age groups; Aged; Aged, 80 and over; Antibodies; Antibodies, Viral - blood; Antibodies, Viral - immunology; Blood & organ donations; Child; Child, Preschool; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Dispatch; Female; Funding; Health aspects; Humans; Immunity (Disease); Infant; Infant, Newborn; Infants; Infection; Infections; Infectious and parasitic diseases; Infectious diseases; Japan - epidemiology; Male; Medical research; Medicine; Medicine, Experimental; Methods; Middle Aged; Population; Prevalence studies (Epidemiology); R; R&D; RC109-216; Research & development; respiratory infections; SARS-CoV-2; SARS-CoV-2 - immunology; Seroepidemiologic Studies; Serology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Testing; vaccine-preventable diseases; Vaccines; Viral antibodies; viruses; Young Adult; zoonoses; Japan; viruses; Japan; elderly; seroprevalence; zoonoses; maternal immunity; infant; respiratory infections; COVID-19; SARS-CoV-2; children; surveillance; vaccine-preventable diseases; seroepidemiology
• ISSN: 1080-6040; 1080-6059; 1080-6059
• DOI: 10.3201/eid3006.231454

We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).